Arterial retention of remnant lipoproteins ex-vivo is increased during insulin resistance due to increased arterial biglycan and production of cholesterol-rich atherogenic particles, that can be improved by ezetimibe in the JCR:LA-cp rat

• Author(s) / Creator(s)

  • Russell, James C.
  • Proctor, Spencer D.
  • Uwiera, Richard R. E.
  • Vine, Donna F.
  • Mangat, Rabban
  • Hassanali, Zahra
  • Cheeseman, Christopher I.
  • Borthwick, Faye
  • Warnakula, Samantha

• Background Literature supports the “response-to-retention” hypothesis—that during insulin resistance, impaired metabolism of remnant lipoproteins can contribute to accelerated cardiovascular disease progression. We used the JCR:LA-cp rat model of metabolic syndrome (MetS) to determine the extent of arterial accumulation of intestinal-derived remnants ex vivo and potential mechanisms that contribute to exacerbated cholesterol deposition in insulin resistance. Methods and Results Arteries from control and MetS (insulin-resistant) JCR:LA-cp rats were perfused ex vivo with Cy5-labeled remnant lipoproteins, and their arterial retention was quantified by confocal microscopy. Arterial proteoglycans were isolated from control and MetS rats at 6, 12, and 32 weeks of age. There was a significant increase in the arterial retention of remnants and in associated cholesterol accumulation in MetS rats as compared to control rats. Mechanistic studies reveal that increased cholesterol deposition is a result of greater arterial biglycan content; longer glycosaminoglycans and increased production of cholesterol-rich intestinal-derived remnants, as compared to controls. Additionally, perfusion of vessels treated with ezetimibe, alone or in combination with simvastatin, with remnants isolated from the respective treatment group reduced ex vivo arterial retention of remnant-derived cholesterol ex vivo as compared to untreated controls. Conclusions Increased progression of atherosclerotic cardiovascular disease in MetS and type 2 diabetes mellitus might be explained in part by an increase in the arterial retention of cholesterol-rich remnants. Furthermore, ezetimibe alone or in combination treatment with simvastatin could be beneficial in ameliorating atherosclerotic cardiovascular disease in insulin resistance and MetS.

• Date created

  2012

• Subjects / Keywords

  • Triglyceride-Rich Remnant Lipoproteins
  • Biglycan
  • Metabolic Syndrome
  • Arterial Remodeling

• Type of Item

  Article (Published)

• DOI

  https://doi.org/10.7939/R3B853X5C

• License

  Attribution-NonCommercial 3.0 Unported